Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis (GKT137831)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03865927
Recruitment Status : Not yet recruiting
First Posted : March 7, 2019
Last Update Posted : March 20, 2019
Sponsor:
Information provided by (Responsible Party):
Steven R. Duncan, MD, University of Alabama at Birmingham

Brief Summary:

A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug will decrease pulmonary injury due to reactive oxygen species (ROS) generated by NOX enzymes, which are believed to play an important role in the development of IPF. Treatment with GKT137831 could result in significant benefit for a lung disease that has, until now, been almost invariably inexorable.

This clinical trial represents the bedside application of a series of NOX translational and basic studies and discoveries, over several years, from the laboratory of Dr. Victor Thannickal.


Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Other: Placebo Oral Tablet Drug: GKT137831 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Following screening assessments, IPF patients who meet all inclusion/exclusion criteria will be randomly assigned to receive one of the following treatments in a ratio of 1:1:

• Arm A (n=30) - GKT137831 Treatment:

GKT137831 will be administered orally, at a dose of 400 mg bid, for a total of 24 weeks.

• Arm B (n=30) - Placebo Treatment:

Arm B subjects will receive matching placebo for the same duration.

Participants will be followed in face-to-face visits with trial personnel every 6 weeks for 24 weeks to assess drug effects and monitor safety during their treatments, and by phone surveillances one month thereafter.

Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of GKT137831 in Patients With Idiopathic Pulmonary Fibrosis
Estimated Study Start Date : August 1, 2019
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : July 31, 2024


Arm Intervention/treatment
Experimental: GKT137831
GKT137831 will be administered orally, at a dose of 400 mg twice daily, for a total of 24 weeks.
Drug: GKT137831
GKT137831 is a NOX enzyme inhibitor

Placebo Comparator: Placebo Oral Tablet
Identically-appearing placebo oral tablets will be administered orally, twice daily, for a total of 24 weeks.
Other: Placebo Oral Tablet
see Arm/Group description




Primary Outcome Measures :
  1. Surrogate biomarker of oxidative stress by mass spectroscopy [ Time Frame: From baseline thru week 24 ]
    Changes in concentrations of circulating o,o'-dityrosine, as determined by mass spectroscopy in plasma, in terms of absolute concentrations and percentages of baseline, will be compared within and between treatment arm participants.


Secondary Outcome Measures :
  1. Collagen degradation product by enzyme linked immunoabsorbant assay [ Time Frame: Baseline to week 24 ]
    Changes in concentrations of the collagen degradation product, serum C1M measured by enzyme linked immunsorbent assays will be compared between baseline values and those at 24 weeks, and between experimental arm and control participants.

  2. Pulmonary function by spirometry [ Time Frame: Baseline to week 24 ]
    Forced vital capacity (FVC), measured by spirometer at baseline, will be compared to values at the conclusion of the study and between the two treatment arms.

  3. Ambulatory ability by measuring walk distance in six minutes [ Time Frame: Baseline to week 24 ]
    Six-minute walk distance (6MWD) will be compared at baseline and as changes from baseline among experimental arm participants and control subjects

  4. Evaluation of safety by adverse events [ Time Frame: Baseline to week 24 ]
    The number and severity of adverse events will be compared between experimental arm participants and those in the control arm.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 40-85 years old.
  2. A diagnosis of IPF that fulfills current American Thoracic Society (ATS) Consensus Criteria.
  3. IPF duration <5 years, based on the date of definitive diagnosis.
  4. Ability and willingness to give informed consent and adhere to study requirements.
  5. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) >70% of predicted values

Exclusion Criteria:

  1. Diagnosis of major comorbidities expected to interfere with study participation
  2. History of malignancy, excluding basal or squamous cell skin cancer and low-risk prostate cancer, the latter defined as stage T1 or T2a, with prostate specific antigen <10 ng/dl. NOX inhibition is not known to promote cancer, and these criteria are within current guidelines.
  3. The occurrence of any acute infection requiring systemic antibiotic therapy within 2 weeks prior to Screening (Visit 1).
  4. Treatment for >14 days within the preceding month with >20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant (e.g., cyclophosphamide, methotrexate, calcineurin inhibitors, etc.), given increased risks of opportunistic infections.
  5. Treatment with any investigational agent within 4 weeks of Screening (Visit 1) or 5 half-lives of the investigational medicinal product (whichever is longer).
  6. Fertile women who do not agree to contraception or abstinence, or who are breast feeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.
  7. Subjects with known hypersensitivity to GKT137831 or its excipients (e.g. capsule "bulking" agents).
  8. A history of bone marrow disorder including aplastic anemia, or marked anemia defined as hemoglobin < 10.0 g/dL (or 6.2 mmol/L).
  9. Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, congestive heart failure (NYHA Class III or IV), or stroke, including a transient ischemic attack.
  10. Evidence of cardiac conducting abnormalities, defined as second or third degree atrial-ventricular (AV) block not successfully treated with a pacemaker, or a personal or family history of long QT syndrome (QTc interval >450 msec for males or 470 msec for females).
  11. End-stage renal disease requiring dialysis.
  12. Undergoing transplantation evaluation, or listed with the United Network for Organ Sharing (UNOS) as a lung transplantation candidate at the time of enrollment in this trial.
  13. Liver function tests (transaminases, alkaline phosphatase, direct and total bilirubin) >3x upper limit of normal values

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03865927


Contacts
Layout table for location contacts
Contact: Steven R Duncan, MD 205-934-5018 srduncan@uabmc.edu

Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Layout table for investigator information
Principal Investigator: Steven R Duncan, MD University of Alabama at Birmingham

Layout table for additonal information
Responsible Party: Steven R. Duncan, MD, PI, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT03865927     History of Changes
Other Study ID Numbers: IRB-300001635
First Posted: March 7, 2019    Key Record Dates
Last Update Posted: March 20, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Steven R. Duncan, MD, University of Alabama at Birmingham:
Reactive oxygen species (ROS)
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase

Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial